|Description||LGD-6972 is an orally bioavailable small molecule glucagon receptor antagonist being developed as an adjunct to diet and exercise to improve glycemic control in adults with T2DM.|
|Brife Description||A glucagon receptor antagonist|
|Solubility||DMSO: ≥ 31 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
Exendin (9-39) is a specific and competitive glucagon-like peptide-1receptor antagonist (Kd = 1.7 nM at cloned human GLP-1 receptors). Exendin (9-39) inhibits i...
L-168,049 is a non-peptidyl, very selective and potent human glucagon receptor (hGR) antagonist. It displays high affinity to human GR with IC50 value of 3.7 nM...
CP-320626, a carboxamide derivative, is a potent glycogen phosphorylase inhibitor and a possible target for type 2 diabetes therapy. CP-320626 is also a potent ...
glucagon receptor antagonists-2
glucagon receptor antagonists-2 is a highly potent antagonist of glucagon receptor .
glucagon receptor antagonists-3
glucagon receptor antagonists-3 is a highly potent antagonist of glucagon receptor .
MK-0893 is a selective glucagon receptor antagonist. It can block glucagon binding to the human GCGR and antagonize glucagon-induced intracellular accumulation ...
BAY-27-9955 is a specific glucagon receptor antagonist.
Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.
CP 316819 has been found to be a glycogen phosphorylase inhibitor and could probably be used in the treatment for glycemic control in type 2 diabetes.
Exenatide acetate is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor with Ki value of 136 pM. It is a 39 amino acid peptide, which incr...
Glucagon receptor antagonists 1
Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist, which is activated by glucagon and is a member of the class B G-protein coupled...
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist (EC50= 0.06 nM) under investigation for treatment of type 2 diabetes.
Ingliforib, with antihyperglycemic and cardioprotective properties, inhibits glycogen phosphorylase.
LGD-6972 is an orally bioavailable small molecule glucagon receptor antagonist being developed as an adjunct to diet and exercise to improve glycemic control in...
glucagon receptor antagonists-4
glucagon receptor antagonists-4 is a potent glucagon receptor antagonist with great oral bioavailability in vivo.
MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM...
des-His1-[Glu9]-Glucagon (1-29) amide
A glucagon receptor antagonist (pA2 = 7.2 for inhibition of glucagon-induced adenylyl cyclase activation in rat liver membranes) that displays no agonist activi...
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model, with IC50 of 56 and 55 nM for rat and human gluca...
Liraglutide is the long-acting analogue of glucagon-like peptide-1 (GLP-1) receptor which could protect b-cells from apoptosis under conditions associated with ...